FDA Grants Fast Track Designation to Gene Therapy for Hemophilia A Patients – Rare Disease Report
Drug Discovery & Development |
FDA Grants Fast Track Designation to Gene Therapy for Hemophilia A Patients
Rare Disease Report Earlier today, Sangamo Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to the company's clinical stage gene therapy candidate for hemophilia A patients – SB-525. Hemophilia A is the effect of … FDA Grants Fast Track Designation to Sangamo's Hemophilia A Gene Therapy Novel Hemophilia A Gene Therapy Gets Fast Track Status FDA grants fast track designation to SB-525 for hemophilia A |
